PD-1 blocking antibody is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is Sun Yat-sen University. The most-studied condition is Nasopharyngeal Carcinoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
NCT06239727 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
|
Phase 3 | Recruiting | Sun Yat-sen University | China |
|
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
|
Phase 2 | Not yet open | Sun Yat-sen University | China |
|
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
NCT04907370 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma
|
Phase 3 | Active, closed | Sun Yat-sen University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Sun Yat-sen University | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name PD-1 blocking antibody as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Sun Yat-sen University. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how PD-1 blocking antibody works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how PD-1 blocking antibody works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists PD-1 blocking antibody (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.